A randomized, three-period, single-dose crossover trial in healthy female volunteers to demonstrate bioequivalence of tafoxiparin following subcutaneous administration via syringe/needle in the abdomen, and via an auto-injector in the abdomen and thigh, respectively.
Latest Information Update: 26 Aug 2025
At a glance
- Drugs Tafoxiparin (Primary)
- Indications Dystocia; Preeclampsia
- Focus Pharmacokinetics
- Sponsors Dilafor
Most Recent Events
- 26 Aug 2025 New trial record